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ABSTRACT 31 
Background: There has been increasing evidence that chronic low-grade inflammation is associated with 32 
mood disorders. However, the findings have been inconsistent because of heterogeneity across studies 33 
and methodological limitations. Our aim is to prospectively evaluate the bi-directional associations 34 
between inflammatory markers including Interleukin (IL)-6, Tumor Necrosis Factor (TNF)-α and high 35 
sensitivity C-reactive protein (hsCRP) with mood disorders.  36 
Methods: The sample consisted of 3,118 participants (53.7% women; mean age: 51.0, s.d. 8.8 years), 37 
randomly selected from the general population, who underwent comprehensive somatic and psychiatric 38 
evaluations at baseline and follow-up (mean follow-up duration = 5.5 years, s.d. 0.6). Current and 39 
remitted mood disorders including bipolar and major depressive disorders (MDD) and its subtypes 40 
(atypical, melancholic, combined atypical and melancholic, and unspecified) were based on semi-41 
structured diagnostic interviews. Inflammatory biomarkers were analyzed in fasting blood samples. 42 
Associations were tested by multiple linear and logistic regression models. 43 
Results: Current combined MDD (β=0.29, 95% CI: 0.03-0.55) and current atypical MDD (β=0.32, 95% CI: 44 
0.10-0.55) at baseline were associated with increased levels of hsCRP at follow-up. There was little 45 
evidence for inflammation markers at baseline predicting mood disorders at follow-up. 46 
Conclusions: The prospective unidirectional association between current MDD subtype with atypical 47 
features and hsCRP levels at follow-up suggests that inflammation may be a consequence of this 48 
condition. The role of inflammation, particularly hsCRP that is critically involved in cardiovascular 49 
diseases, warrants further study. Future research that examines potential influences of medications on 50 
inflammatory processes is indicated. 51 
 52 
Key-words: mood disorders; atypical depression; pro-inflammatory cytokines; C-Reactive protein; 53 
prospective study; cardiovascular risk factors.  54 
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INTRODUCTION 55 
Mood disorders and cardiovascular diseases (CVD) are among the highest sources of morbidity and 56 
premature mortality worldwide (GBD 2015 DALYs & HALE Collaborators, 2016). Moreover, their high 57 
comorbidity (Van der Kooy et al. 2007; Glaus et al. 2013) is associated with even greater disability 58 
adjusted life years than either disorder alone (Charlson et al. 2013). An increasingly recognized 59 
mechanism to explain comorbidity of CVD with mood disorders is common underlying low-grade 60 
inflammation. Specifically, there is a consistent association between circulating levels of pro-61 
inflammatory cytokines, such as Interleukin (IL)-1β, IL-6 and Tumor Necrosis Factor (TNF)-α, and the 62 
acute phase reactant C-Reactive Protein (CRP) with both mood disorders (Howren et al. 2009; Dowlati et 63 
al. 2010; Modabbernia et al. 2013; Glaus et al. 2014)  and CVD (Baune et al. 2012). Alternatively, such 64 
inflammatory processes could also provoke mood disorders or CVD through, for instance, stress- 65 
induced perturbation of the Hypothalamic-Pituitary-Adrenal (HPA) axis (Rosmond & Bjorntorp, 2000; 66 
Watson, 2006). Conversely, mood disorders could induce inflammation through similar mechanisms 67 
(Rosenblat et al. 2014). 68 
Although the bulk of prospective research on inflammatory markers and CVD has focused on major 69 
depression, comparably few studies have examined the extent to which associations extend to other 70 
mood disorders, such as bipolar disorder (BPD)(Van der Kooy et al. 2007; Modabbernia et al. 2013). In a 71 
recent meta-analysis of 25 cross-sectional studies and 2 longitudinal analyses (changes in CRP levels 72 
before and after treatment for mania and depression), BPD disorder was associated with increased 73 
levels of CRP (Fernandes et al. 2016). In another meta-analysis of 30 cross-sectional studies, BPD 74 
disorder was associated with increased levels of IL-6 and TNF-α (Modabbernia et al. 2013). 75 
Moreover, few longitudinal studies have examined depressive subtypes (Rothermundt et al. 2001; 76 
Kaestner et al. 2005; Yoon et al. 2012; Lamers et al. 2013; Rudolf et al. 2014; Glaus et al. 2014) that have 77 
been shown to be highly heterogeneous (Schmidt et al. 2011; Lopresti et al. 2014) and even fewer 78 
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studies have considered the well-established comorbidity among mental disorders (Stewart et al. 2009; 79 
Kivimaki et al. 2014) or current versus past disorders (Whooley et al. 2008).  80 
 81 
With respect to directionality, longitudinal studies of the links between mood disorders and 82 
inflammation have predominantly been performed in patients with a major depressive disorder (MDD) 83 
(Valkanova et al. 2013; Chocano-Bedoya et al. 2014; Kivimaki et al. 2014; Tully et al. 2015). Recent meta-84 
analyses (Valkanova et al. 2013) and more recent studies (Chocano-Bedoya et al. 2014; Tully et al. 2015) 85 
have shown that these associations between inflammatory factors and mood disorders may be partially 86 
attributable to potential confounders, including body mass index (BMI) and smoking. Similar findings 87 
regarding mediation by BMI and behavioral cardiovascular risk factors (CVRFs) have also emerged from 88 
prospective studies of inflammation as a potential consequence of mood disorders (Matthews et al. 89 
2007; Stewart et al. 2009; Gimeno et al. 2009; Duivis et al. 2011). However, to date, the few studies that 90 
have examined the bi-directional associations simultaneously have yielded conflicting results (Stewart et 91 
al. 2009; Gimeno et al. 2009; Matthews et al. 2010; Duivis et al. 2011). The aggregate findings from 92 
these studies highlight the importance of incorporating CVRFs including diabetes (Marques-Vidal et al. 93 
2012a), overweight (Marques-Vidal et al. 2012b; Kiecolt-Glaser et al. 2015), smoking (Yanbaeva et al. 94 
2007), chronic alcohol consumption (Achur et al. 2010) and physical inactivity (Hamer, 2007; Kiecolt-95 
Glaser et al. 2015) along with depression and anxiety (e.g.(Agosti & Levin, 2006; Mezuk et al. 2008; 96 
Chaiton et al. 2009; Luppino et al. 2010; Anthenelli, 2010; Glaus et al. 2013; Lasserre et al. 2014; Kiecolt-97 
Glaser et al. 2015)), when examining the association with inflammation.  98 
 99 
Our previous cross-sectional findings from a large community cohort revealed that there were 100 
significantly elevated levels of high sensitivity CRP (hsCRP) among those with the atypical subtype of 101 
depression and bipolar disorders, but these associations were explained by concurrent CVRFs, such as 102 
BMI, diabetes and hypertension (Glaus et al. 2014). In the present study, we extend these earlier cross-103 
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sectional analyses from our large community-based cohort in Lausanne, Switzerland, to examine the 104 
directionality, specificity, timing, and potential causal versus common etiologic mechanisms for 105 
associations between mood disorders and markers of a chronic low-grade inflammation by addressing 106 
the following aims: (1) to evaluate the 5-year prospective associations between mood disorders 107 
including their subtypes, and changes in circulating levels of specific inflammatory markers (IL-6, TNF-α, 108 
hsCRP) to determine the specificity of the associations; (2) to assess the directionality of links between 109 
inflammatory markers and mood disorders; (3) to examine whether the markers comprise state versus 110 
trait indices by comparing remitted versus current disorders, as well as incident cases; and (4) to 111 
examine the role of health behaviors, CVRFs, and treatment factors that may influence this association. 112 
Based on our previous cross-sectional findings (Glaus et al. 2014) as well as those of other studies 113 
(Lamers et al. 2013; Hickman et al. 2014; Rudolf et al. 2014), we hypothesized that there would be an 114 
association between the atypical subtype of depression and increased levels of inflammatory markers, 115 
whereas other subtypes of major depressive disorders were not expected to be associated with 116 
increased inflammation. 117 
 118 
 119 
METHODS AND MATERIALS 120 
Study sample 121 
We drew the data for the present investigation from CoLaus|PsyCoLaus (Firmann et al. 2008; Preisig et 122 
al. 2009), a cohort study designed to prospectively assess the associations between mental disorders 123 
and CVD or CVRFs in the community. The sample was randomly selected from the civil register of the 124 
city of Lausanne (Switzerland) in 2003. Sixty-seven percent of participants between 35 and 66 years-of 125 
age (n=5,535), who underwent the physical exam between 2003 and 2006, also accepted the psychiatric 126 
evaluation, resulting in a sample of 3,719 individuals at baseline (Preisig et al. 2009) (see Figure 1, flow 127 
chart). The mean interval between the physical and psychiatric evaluations at baseline was 1.3 years 128 
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(s.d. 0.5). Five years later, 3,191 participated in the physical exam (85.8% participation). Among them, 61 129 
participants were excluded due to missing information on inflammatory markers both at baseline and 130 
follow-up, 9 subjects were excluded due to missing information on mental disorders and 3 subjects were 131 
excluded due to missing information on CVRFs. The final sample used to examine associations between 132 
mood disorders at baseline and inflammation at follow-up consisted of 3,118 participants in total (53.7% 133 
women; mean age: 51.0, s.d. 8.8 years): 2,796 participants were analyzed for cytokines levels, and 2,896 134 
for hsCRP levels. The mean follow-up duration for the physical examination was 5.5 years (s.d. 0.6 135 
years). The mean follow-up duration for the mental health assessment was also 5.5 years (s.d. 0.8). The 136 
number of participants with data on the psychiatric evaluation at follow-up was 2,840. Among them, 137 
258 participants were excluded due to missing information on inflammatory markers and 2 participants 138 
due to missing information on CVRFs. The resulting number of participants used to determine the 139 
association between inflammation at baseline and mental disorders at follow-up was 2,580. The 140 
Institutional Ethics’ Committee of the University of Lausanne approved the CoLaus and the PsyCoLaus 141 
study. All participants provided written informed consent for the study protocol. 142 
 143 
Measurements 144 
Mood disorders and comorbid disorders 145 
Mental disorders at baseline and follow-up were assessed using the French version (Leboyer et al. 1995) 146 
of the semi-structured Diagnostic Interview for Genetic Studies (DIGS), which was developed and 147 
validated by the National Institute of Mental Health (Nurnberger et al. 1994). The French version of this 148 
instrument revealed adequate inter-rater and test-retest reliability for major mood (Preisig et al. 1999) 149 
and substance use disorders (Berney et al. 2002). The DIGS was completed with sections on generalized 150 
anxiety and phobia disorders using questions from the Schedule for Affective Disorders and 151 
Schizophrenia-Lifetime and Anxiety disorder version (SADS-LA (Endicott & Spitzer, 1978)), which also 152 
revealed satisfactory test-retest reliability (Leboyer et al. 1991; Rougemont-Buecking et al. 2008). 153 
8 
 
Interviewers were required to be masters-level psychologists and were trained over a two-month 154 
period. In order to provide ongoing supervision throughout the study, each interview and diagnostic 155 
assignment was reviewed by an experienced senior psychologist. Diagnoses were assigned according to 156 
the DSM-IV. Following Angst et al. (Angst et al. 2006), MDD was subtyped into: 1) MDD with at least one 157 
atypical and one melancholic episode or MDD with atypical and melancholic features simultaneously 158 
(combined type); 2) MDD with at least one atypical (but no melancholic) episode; 3) MDD with at least 159 
one melancholic (but no atypical) episode; and 4) MDD with neither atypical nor melancholic episodes 160 
(unspecified type). We defined MDD as current if it was present at the time of the physical evaluation.  161 
 162 
Inflammatory markers 163 
HsCRP was assessed during baseline and follow-up physical evaluations using immunoassay and latex HS 164 
(IMMULITE 1000-High, Diagnostic Products Corporation, LA, CA, USA), with maximum intra- and 165 
interbatch coefficients of variation of 1.3% and 4.6%, respectively (Firmann et al. 2008). Subjects with a 166 
hsCRP level higher than 10 mg/l were excluded as such an elevation is likely to be attributable to acute 167 
infection (Pearson et al. 2003). For the baseline and follow-up cytokine measurements, serum was 168 
preferred to plasma, as it has been shown that different anticoagulants may differentially affect 169 
absolute cytokine levels (Skeppholm et al. 2008). Serum samples were stored at -80°C before 170 
assessment and sent on dry ice to the laboratory. As previously described, cytokine levels were 171 
measured using a multiplexed particle-based flow cytometric cytokine assay (Marques-Vidal et al. 2011). 172 
Lower detection limits (LOD) for IL-6 and TNF-α were 0.2 pg/ml. Good agreement between signal and 173 
cytokine was found within the assay range (R2 ≥ 0.99). 174 
 175 
Covariates 176 
Data were collected on age, race (Caucasian versus non-Caucasian), marital status (living alone versus 177 
living with someone) and health-related behaviors at baseline including smoking (never, former, 178 
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current) and physical inactivity (no or low versus at least 20 minutes twice a week). Information on 179 
socio-economic status (SES) and on psychotropic drug treatment was derived from the DIGS. The level of 180 
SES was assessed using the Hollingshead scale (Hollingshead, 1975). The section on psychotropic drug 181 
treatment covered all types of antidepressants, mood stabilizers (lithium and anti-epileptics) and 182 
antipsychotics. Moreover, information on aspirin and statin use was collected during the baseline 183 
physical evaluation (never versus occasional versus regular use). The following biological variables were 184 
measured during the baseline physical evaluation: BMI (weight in kilograms divided by height in meters 185 
squared), diabetes (fasting blood glucose ≥ 7 mmol/l or treatment for diabetes), dyslipidemia (HDL-186 
cholesterol < 1 mmol/l, or LDL-cholesterol ≥ 4.1 mmol/l, or triglycerides ≥ 2.2 mmol/l, or treatment with 187 
a lipid-lowering drug), hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 188 
90 mmHg, or treatment for hypertension). 189 
 190 
Statistical analysis 191 
Statistical analyses were conducted using the Statistical Analysis System (SAS Institute Inc., Cary, NC, 192 
USA), version 9.3 for Windows. Age was standardized. Descriptive data for demographic characteristics, 193 
comorbid disorders, medication, health-related behaviors, physical risk factors for CVD and 194 
inflammatory marker levels were derived by lifetime mood disorders and Chi-square and Kruskal-Wallis 195 
tests were used to determine the difference between mood disorders. The Benjamini-Hochberg false 196 
discovery method (Benjamini & Hochberg, 1995) was employed to correct for multiple tests for all 197 
depressive subtypes except the pre-specified association with the atypical subtype of depression. 198 
Associations between current and remitted mood disorders at baseline and changes in inflammatory 199 
markers at follow-up were determined using multiple linear regression models. Box-Cox transformation 200 
was applied to the response variable whenever a deviation from fundamental assumptions was 201 
observed. All three inflammatory markers were transformed: for the dependent variables, inflammatory 202 
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markers were log-transformed, whereas for the independent variables, inflammatory markers were 203 
normalized and log-transformed. Values below the LOD of 0.2 [pg/ml] (i.e., 5% of values for IL-6, 0.5% of 204 
values for TNF-α) were considered as censored observations. IL-6 and TNF-α were analyzed with the 205 
qualitative and limited dependent variable model (QLIM) with the threshold of -1.65 [log (pg/ml)] as the 206 
meaningful lower bound of observed values. 207 
A multiple linear regression model was performed on naturally log-transformed and standardized 208 
observed values. Three models of increasing complexity were computed. Model 1 included one single 209 
mood disorder (current and remitted) at a time as the independent variable, adjusted for the 210 
corresponding inflammatory marker at baseline. Model 2 included current and remitted mood disorders 211 
simultaneously in order to determine the associations of specific mood disorder with inflammatory 212 
markers at follow-up, adjusting for the length of follow-up, sociodemographic characteristics (sex, age, 213 
SES, race and marital status), comorbid disorders (anxiety and substance use disorders), health-related 214 
behaviors and physical risk factors for CVD at baseline and the covariate of Model 1. In case of 215 
significant associations, additional models also adjusted for the occurrence of new episodes in order to 216 
test whether the associations persist after the offset of depressive episodes. Similar models adjusted for 217 
the occurrence of new physical risk factors for CVD during the follow-up in order to test whether the 218 
prospective associations between mood disorders and inflammation marker levels were independent of 219 
the occurrence of these new risk factors. 220 
Associations between inflammatory markers at baseline and a history of mood disorders during the 221 
follow-up period were determined using logistic regression models. Two models were computed. Model 222 
1 included all inflammatory markers simultaneously, adjusting for the corresponding history of mood 223 
disorder at baseline. Model 2 was further adjusted for the length of follow-up, sociodemographic 224 
characteristics, health-related behaviors and physical risk factors for CVD.  225 
 226 
RESULTS 227 
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Sample characteristics 228 
The description of the cohort of 3,118 participants used for the assessment of the prospective 229 
associations between mood disorders at baseline and the concentrations of inflammatory markers at 230 
follow-up is presented in Table 1. The groups (bipolar disorder, MDD subtypes and no history of mood 231 
disorders) differed with respect to sex, age, marital status, comorbid disorders, medication, current 232 
smoking status, BMI and hypertension. Moreover, the groups also differed with respect to hsCRP levels 233 
at baseline and at follow-up.  234 
Associations between mood disorders at baseline and inflammatory markers at follow-up 235 
Associations between current and remitted mood disorders at baseline and changes in levels of 236 
inflammatory markers are presented in Table 2 and 3. When models were only adjusted for the 237 
corresponding inflammatory marker at baseline (Table 2), current MDD, as well as the current combined 238 
and atypical MDD subtypes were associated with increased hsCRP levels. Moreover, current combined 239 
MDD was associated with decreased IL-6 levels. No significant associations were found for remitted 240 
mood disorders with inflammatory markers. When the model was further adjusted for potential 241 
confounders, MDD was no longer significantly associated with hsCRP levels (β=0.09, 95%CI -0.02-0.21). 242 
In contrast, current combined MDD was associated with increased hsCRP levels and decreased IL-6 243 
levels and current atypical MDD was associated with increased hsCRP levels at follow-up (Table 3). 244 
Moreover, remitted melancholic MDD was associated with decreased IL-6 levels at follow-up in the fully 245 
adjusted model (Table 3). Additional analyses revealed that the occurrence of new mood episodes 246 
during the follow-up did not affect the size of the associations between current mood disorders at 247 
baseline and the hsCRP at follow-up. Similarly, the occurrence of incident physical risk factors for CVD 248 
did not account for the associations between current combined MDD or current atypical MDD at 249 
baseline and the hsCRP at follow-up. 250 
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Since an association was found between the atypical MDD subtype and increased hsCRP levels at follow-251 
up, we also looked at the correlation between the age of onset of atypical MDD and inflammatory 252 
markers. Interestingly, later atypical MDD onset was correlated with increased hsCRP levels (Pearson 253 
correlation = 0.16, p-value = 0.0214). 254 
Associations between inflammatory markers at baseline and mood disorders at follow-up 255 
Regarding the associations between inflammatory markers at baseline and mood disorders at follow-up, 256 
higher levels of TNF-α were associated with a decreased risk of MDD and of the MDD atypical and 257 
unspecified subtypes after controlling for a history of depression at baseline (Table 4). After controlling 258 
for all the covariates (Model 2), higher levels of TNF-α were still associated with a decreased risk of MDD 259 
and of the MDD unspecified subtype, but not with the MDD atypical subtype. Moreover, levels of IL-6 260 
and hsCRP at baseline were not associated with any mood disorders at follow-up. 261 
We also tested the associations between inflammatory markers at baseline and incident cases of mood 262 
disorders excluding subjects that already had a lifetime history of this disorder at baseline. However, no 263 
significant associations were found (results not shown). 264 
However, none of these associations remained significant after correction for multiple testing that was 265 
conducted on all subtypes of depression except the pre-specified atypical subtype. 266 
Additional analyses 267 
In order to examine the potential influence of concurrent medication use on these associations, we 268 
examined the effects of mood stabilizers and antidepressants on changes in inflammatory marker levels 269 
over time. We found that lower IL-6 levels were associated with mood stabilizer use in those with BPD 270 
(β=-1.33, p-value=0.036), but no differences were found for antidepressant use in the MDD subgroups. 271 
 272 
DISCUSSION 273 
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The present study prospectively assessed the bi-directional 5-year associations between mood disorder 274 
and its subtypes with several inflammatory markers with serial adjustments for sociodemographic, 275 
comorbid mental disorders, medication use, health behaviors, and CVRFs, in a large community sample 276 
of adults. Our results showed differential associations depending on temporal ordering, current versus 277 
remitted status of the mood disorder, the specific type of mood disorder and different indices of 278 
inflammation. The major finding is that there is an association between the current atypical subtype of 279 
MDD at baseline with increased levels of hsCRP at follow up, whereas inflammatory levels at baseline 280 
were not associated with subsequent atypical MDD at follow-up. This unidirectional association 281 
indicates that this disorder may be causally related to increased inflammation, rather than inflammation 282 
comprising a vulnerability factor for mood disorders.  Future studies with more closely timed follow-up 283 
assessments may inform potential mechanisms for elevation of hsCRP among those with this condition. 284 
Our finding of unidirectional associations between MDD and elevated hsCRP levels appear to be specific 285 
to the atypical subtype of MDD, which is characterized by somatic symptoms including sleep, energy and 286 
eating behavior (Rothermundt et al. 2001; Kaestner et al. 2005; Stewart et al. 2009; Duivis et al. 2011; 287 
Copeland et al. 2012; Lamers et al. 2013; Hickman et al. 2014; Rudolf et al. 2014; Schmidt et al. 2014; 288 
Glaus et al. 2014). This finding suggests that the atypical MDD is associated with more detectable 289 
immune dysfunction. This could be a primary characteristic of this disorder or reflect other indirect 290 
factors, such as greater disturbance of circadian systems, HPA systems or other relevant immune 291 
modulators. A similar link between cumulative depressive episodes and CRP at follow-up in a 292 
prospective study of a community sample of youth would confirm this explanation and further imply 293 
that the associations observed herein may be present across the life span (Copeland et al. 2012).The 294 
specificity of the findings with respect to the atypical subtype rather than BPD (Modabbernia et al. 295 
2013), as shown in previous studies of adults and youth, further suggests that the somatic 296 
manifestations of depression may be etiologically related to inflammation. However, the power to test 297 
the association between BPD and inflammation was reduced because of the relatively low numbers of 298 
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people with BPD in this sample. Interestingly, a previous case-control study (Cunha et al. 2008) that 299 
evaluated BPD patients in different phases of their illness found increased hsCRP levels in patients with a 300 
current manic episode compared to depressed, euthymic patients and healthy controls. Moreover, 301 
recent studies have shown that mania, and to a lesser extent depression, in BPD patients are associated 302 
with pro-inflammatory cytokines (Muneer, 2016). To our knowledge, no previous studies have examined 303 
depressive subtypes in BPD compared to MDD patients and healthy controls. Future prospective studies 304 
should further investigate the different state-related associations between mood disorder subtypes and 305 
inflammation. 306 
The lack of association between inflammatory markers at baseline and subsequent mood disorders at 307 
follow-up suggests that inflammation may not be a risk factor for the onset of mood disorders. This 308 
result extends the findings of two previous longitudinal studies, which found that depression predicted 309 
higher inflammation, whereas inflammation did not predict depression (Stewart et al. 2009; Duivis et al. 310 
2011). However, our results do not confirm findings from previous studies that focused on depressive 311 
symptoms rather than disorder (Gimeno et al. 2009; Matthews et al. 2010; Valkanova et al. 2013; Tully 312 
et al. 2015). These discrepancies could be due to methodological differences. Moreover, no depressive 313 
subtypes were analyzed. 314 
 315 
Our findings were restricted to the hsCRP, rather than the pro-inflammatory cytokines. CRP has been 316 
shown to lead to broader manifestations of the metabolic syndrome, particularly among those with 317 
current disorders rather than symptoms alone (Gimeno et al. 2009; Matthews et al. 2010; Valkanova et 318 
al. 2013). This further suggests that the physical symptoms of these conditions may induce a stress-like 319 
physiologic reaction in affected individuals.  Accordingly, depression may contribute to a chronic low-320 
grade inflammatory state, which, in turn, might lead to a vascular pathology and ultimately to 321 
atherosclerotic vascular disease (Wagner et al. 2015). Several potential pathophysiological mechanisms 322 
have been suggested to underlie the association between depression and higher inflammation, including 323 
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HPA axis activation and oxidative stress (Rosenblat et al. 2014). However, future longitudinal studies are 324 
needed to confirm these potential mechanisms. 325 
Our evaluation of medication use at index evaluation as a possible explanation for changes in 326 
inflammatory markers revealed that mood stabilizer use was associated with lower IL-6 levels at follow-327 
up. This suggests that future studies should examine the specific influences of mood stabilizers not only 328 
on symptom relief but also on concomitant inflammatory factors. However, no such changes emerged 329 
for inflammatory markers and other mood disorder subtypes. 330 
Our results should be interpreted in the context of several limitations. First, there was an interval of 331 
almost one year between the physical and the psychiatric evaluations. Although the timing of depressive 332 
episodes was elicited in our diagnostic interviews, we cannot exclude misclassification regarding the 333 
"current" status of disorders at the time of the physical evaluation. Second, inflammatory markers were 334 
only assessed twice, once at baseline and 5.5 years later at follow-up, which may only partially reflect 335 
the dynamic temporal relationship between mood disorders and inflammatory markers over time. 336 
However, despite this limitation, our findings still indicate that there may be an enduring increase of 337 
inflammation in individuals with specific subtypes of mood disorders. Third, low-grade inflammation was 338 
assessed through hsCRP and the two pro-inflammatory cytokines IL-6 and TNF-α. We did not include 339 
additional pro-inflammatory (i.e. IL-1β, IL-2, IFN-γ) and anti-inflammatory (i.e. IL-4, IL-8, IL-10) cytokines, 340 
and other potential biomarkers of inflammation, such as cortisol, leucocytes and thrombocytes. Fourth, 341 
with only 55 subjects with a lifetime history of BPD at baseline we did not have sufficient power to 342 
detect differences in inflammation levels at follow-up as a function of the BPD status at baseline. 343 
Despite these limitations, this is one of the largest prospective studies of a community sample, with the 344 
hitherto longest follow-up period. It is the first study to investigate the full range of mood disorder 345 
subtypes. 346 
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These prospective data from a large community sample show that unidirectional association between 347 
current MDD subtypes with atypical features and increased hsCRP levels at a more than 5-year follow-up 348 
may be a consequence of this condition. Further prospective studies with repeated assessments of 349 
inflammatory markers earlier in the development of mood disorders are required to examine potential 350 
influences of medications on inflammatory processes. 351 
 352 
  353 
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TABLE 1: Sociodemographic, Medication, Health-Related Behaviors, Physical Risk Factors for Cardiovascular Disorders and Inflammatory markers by 
lifetime mood disorders at baseline (n=3118) 
 
Bipolar disorder 
 
MDD 
 Major depressive disorder subtypes  
No Mood 
Disorders 
 
p-value a 
   Combined MDD  Atypical MDD  
Melancholic 
MDD 
 Unspecified 
MDD 
  
 n = 55  n = 1367  n = 171  n = 206  n = 362  n = 628  n = 1696  
 Current n = 2  Current n = 213  Current n = 36  Current n = 47  Current n = 49  Current n = 81     
 Remitted n = 53  Remitted n = 1154  Remitted n = 135  Remitted n = 159  Remitted n = 313  Remitted n = 547     
Sociodemographics                       
Length of follow-up, mean (SD) 5.62 (0.71)  5.51 (0.59)  5.46 (0.61)  5.51 (0.55)  5.53 (0.57)  5.51 (0.61)  5.54 (0.63)  0.568b 
Sex, n (%)                       
Female 26 (47.27)  899 (65.76)  123 (71.93)  148 (71.84)  245 (67.68)  383 (60.99)  748 (44.10)  
<.0001 
Male 29 (52.73)  468 (34.24)  48 (28.07)  58 (28.16)  117 (32.32)  245 (39.01)  948 (55.90)  
Age, mean (SD) 51.15 (8.43)  50.33 (8.71)  50.64 (8.84)  49.56 (8.68)  50.60 (8.69)  50.35 (8.70)  51.53 (8.87)  0.007b 
Socio-economic status, mean (SD) 3.33 (1.29)  3.42 (1.26)  3.31 (1.24)  3.34 (1.21)  3.39 (1.34)  3.50 (1.23)  3.42 (1.28)  0.381b 
Ethnicity, n (%)                       
Caucasian 55 (100.00)  1251 (91.51)  160 (93.57)  191 (92.72)  331 (91.44)  569 (90.61)  1575 (92.87)  
0.119 
Other 0 (0.00)  116 (8.49)  11 (6.43)  15 (7.28)  31 (8.56)  59 (9.39)  121 (7.13)  
Marital status, n (%)                       
Living alone 25 (45.45)  547 (40.01)  65 (38.01)  93 (45.15)  153 (42.27)  236 (37.58)  429 (25.29)  
<.0001 
Living in couple 30 (54.55)  820 (59.99)  106 (61.99)  113 (54.85)  209 (57.73)  392 (62.42)  1267 (74.71)  
Comorbid disorders, n (%)                       
Anxiety disorders 22 (40.00)  340 (24.87)  56 (32.75)  51 (24.76)  94 (25.97)  139 (22.13)  204 (12.03)  <.0001 
Substance use disorders 13 (23.64)  218 (15.95)  31 (18.13)  22 (10.68)  60 (16.57)  105 (16.72)  240 (14.15)  0.060 
Medication, n (%)                       
Antidipressants 28 (50.91)  522 (38.19)  86 (50.29)  91 (44.17)  176 (48.62)  169 (26.91)  90 (5.31)  <.0001 
Mood stabilizers 12 (21.82)  8 (0.59)  1 (0.58)  1 (0.49)  5 (1.38)  1 (0.16)  2 (0.12)  <.0001 
Antipsychotics 10 (18.18)  32 (2.34)  8 (4.68)  4 (1.94)  9 (2.49)  11 (1.75)  9 (0.53)  <.0001 
Aspirin 10 (18.18)  121 (8.85)  17 (9.94)  24 (11.65)  33 (9.12)  47 (7.48)  130 (7.67)  0.030 
Statins 6 (10.91)  93 (6.80)  12 (7.02)  14 (6.80)  23 (6.35)  44 (7.01)  132 (7.78)  0.819 
Health-related behaviors, n (%)                       
Former smoking 21 (38.18)  441 (32.26)  49 (28.65)  64 (31.07)  112 (30.94)  216 (34.39)  569 (33.55)  0.557 
Current smoking 21 (38.18)  417 (30.50)  62 (36.26)  54 (26.21)  102 (28.18)  199 (31.69)  423 (24.94)  0.001 
Physical inactivity 21 (38.18)  600 (43.89)  78 (45.61)  97 (47.09)  148 (40.88)  277 (44.11)  737 (43.46)  0.681 
Biological risk factors                       
Body mass index, mean (SD) 26.46 (4.99)  25.13 (4.47)  25.66 (5.21)  26.46 (4.83)  24.56 (4.16)  24.87 (4.20)  25.46 (4.23)  0.000b 
Diabetes, n (%) 3 (5.45)  57 (4.17)  11 (6.43)  9 (4.37)  9 (2.49)  28 (4.46)  88 (5.19)  0.293 
Dyslypidemia, n (%) 20 (36.36)  406 (29.70)  54 (31.58)  60 (29.13)  104 (28.73)  188 (29.94)  563 (33.20)  0.379 
Hypertension, n (%) 13 (23.64)  364 (26.63)  44 (25.73)  67 (32.52)  95 (26.24)  158 (25.16)  525 (30.96)  0.036 
Inflammatory markers at baseline, Median (IQR)                     
Interleukin-6 1.24 (0.35-2.64)  1.19 (0.50-3.04)  1.25 (0.63-3.37)  1.29 (0.56-3.25)  1.22 (0.52-2.73)  1.13 (0.45-3.04)  1.34 (0.60-3.36)  0.106 
Tumor Necrosis Factor-α 2.52 (1.65-3.91)  2.69 (1.62-4.29)  2.54 (1.62-4.17)  2.89 (1.71-4.81)  2.72 (1.63-4.26)  2.61 (1.57-4.26)  2.87 (1.85-4.47)  0.067 
High-sensitivity C-Reactive protein 1.30 (0.70-3.10)  1.00 (0.50-2.10)  0.90 (0.50-2.20)  1.10 (0.60-2.60)  1.00 (0.50-2.20)  1.00 (0.50-2.00)  1.00 (0.50-2.20)  0.030 
Inflammatory markers at follow-up, Median (IQR)                     
Interleukin-6 2.49 (1.25-6.10)  2.31 (0.89-7.79)  2.44 (0.73-5.54)  2.51 (0.80-8.92)  2.05 (0.85-7.27)  2.35 (0.93-8.02)  2.82 (0.98-8.83)  0.100 
Tumor Necrosis Factor-α 5.35 (2.98-7.86)  4.48 (2.43-8.07)  4.52 (2.17-7.51)  4.25 (2.33-9.14)  4.56 (2.80-7.89)  4.53 (2.42-8.09)  4.72 (2.52-8.27)  0.826 
High-sensitivity C-Reactive protein 1.60 (0.90-3.40)  1.10 (0.60-2.50)  1.20 (0.70-2.60)  1.40 (0.70-3.20)  1.10 (0.60-2.70)  1.10 (0.50-2.35)  1.20 (0.60-2.50)  0.018 
Abbreviations: SD = standard deviation; MDD = major depressive disorder; IQR=Interquartile range (the 25% and 75% are provided). 
Median and IQR of inflammatory markers were not logarithmically transformed (n IL-6, TNF- α = 2796, n hsCRP = 2896).  
a Chi-square Test; b Kruskal-Wallis Test.
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TABLE 2: Associations between current and remitted mood disorders at baseline and inflammatory markers at follow-up 
  Interleukin 6 [pg/ml]   Tumor Necrosis Factor-α [pg/ml]   hs C-Reactive Protein [mg/l] 
 βa (95% CI) p-value  βa (95% CI) p-value  βa (95% CI) p-value 
Current diagnoses       
Bipolar Disorder  -1.29 (-3.51-0.93) 0.256  0.17 (-1.22-1.56) 0.810  -0.61 (-1.66-0.43) 0.251 
Major Depressive Disorder -0.10 (-0.33-0.14) 0.429  -0.06 (-0.21-0.09) 0.427  0.12 (0.01-0.22) 0.037 
MDD Combined Subtype -0.69 (-1.23/-0.14) 0.014  -0.27 (-0.61-0.08) 0.127  0.33 (0.07-0.59) 0.011 
MDD Atypical Subtype  -0.12 (-0.62-0.37) 0.627  0.04 (-0.27-0.35) 0.809  0.36 (0.14-0.58) 0.002 
MDD Melancholic Subtype -0.07 (-0.55-0.42) 0.785  -0.18 (-0.48-0.12) 0.247  -0.09 (-0.31-0.13) 0.406 
MDD Unspecified Subtype 0.19 (-0.19-0.56) 0.322   0.06 (-0.17-0.29) 0.622   -0.02 (-0.19-0.16) 0.855 
Remitted diagnoses                       
Bipolar Disorder  0.14 (-0.33-0.60) 0.567  0.09 (-0.20-0.38) 0.550  0.18 (-0.04-0.39) 0.111 
Major Depressive Disorder -0.07 (-0.19-0.06) 0.300  -0.00 (-0.08-0.07) 0.925  -0.03 (-0.08-0.03) 0.384 
MDD Combined Subtype -0.05 (-0.34-0.24) 0.740  0.00 (-0.18-0.19) 0.984  -0.08 (-0.22-0.05) 0.226 
MDD Atypical Subtype  -0.02 (-0.29-0.24) 0.856  -0.11 (-0.28-0.06) 0.189  -0.03 (-0.16-0.10) 0.640 
MDD Melancholic Subtype -0.19 (-0.38-0.01) 0.069  0.06 (-0.07-0.18) 0.379  0.01 (-0.08-0.10) 0.781 
MDD Unspecified Subtype 0.03 (-0.13-0.19) 0.691   -0.00 (-0.10-0.10) 0.954   -0.02 (-0.09-0.06) 0.675 
Abbreviations: β = β-estimator; CI = confidence interval; MDD = major depressive disorder. 
Models adjusted for the corresponding inflammatory marker at baseline, “No mood disorders” considered as the 
comparison group. 
ᵃ multiple regression with logarithmically transformed cytokine (n = 2796) or hsCRP concentrations (n = 2896). 
Statistically significant results are in bold. 
p-values are in italic. 
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TABLE 3: Adjusted associations between current and remitted mood disorders at baseline and inflammatory markers at follow-up 
  Interleukin 6 [pg/ml]   Tumor Necrosis Factor-α [pg/ml]   hs C-Reactive Protein [mg/l] 
  βa (95% CI) p-value  βa (95% CI) p-value  βa (95% CI) p-value 
Current diagnoses       
Bipolar Disorder  -- -- --  -- -- --  -- -- -- 
MDD Combined Subtype -0.74 (-1.30\-0.18) 0.010  -0.26 (-0.61-0.09) 0.141  0.29 (0.03-0.55) 0.026 
MDD Atypical Subtype  -0.17 (-0.67-0.34) 0.521  0.04 (-0.28-0.35) 0.814  0.32 (0.10-0.55) 0.005 
MDD Melancholic Subtype -0.14 (-0.64-0.35) 0.573  -0.13 (-0.44-0.18) 0.412  -0.10 (-0.33-0.12) 0.362 
MDD Unspecified Subtype 0.14 (-0.25-0.52) 0.478   0.08 (-0.16-0.32) 0.521   -0.01 (-0.19-0.16) 0.889 
Remitted diagnoses                       
Bipolar Disorder  0.04 (-0.46-0.55) 0.872  -0.01 (-0.32-0.30) 0.954 
 
0.13 (-0.10-0.37) 0.261 
MDD Combined Subtype -0.13 (-0.44-0.18) 0.415  -0.01 (-0.20-0.18) 0.916 
 
-0.09 (-0.23-0.05) 0.202 
MDD Atypical Subtype  -0.10 (-0.38-0.19) 0.499  -0.10 (-0.28-0.08) 0.268 
 
-0.04 (-0.17-0.09) 0.552 
MDD Melancholic Subtype -0.23 (-0.45\-0.02) 0.036  0.06 (-0.07-0.20) 0.372 
 
0.03 (-0.07-0.13) 0.517 
MDD Unspecified Subtype -0.04 (-0.21-0.13) 0.649   0.00 (-0.10-0.11) 0.970   0.00 (-0.08-0.08) 0.983 
Abbreviations: β = β-estimator; CI = confidence interval; MDD = major depressive disorder. 
Models adjusted for the corresponding inflammatory marker at baseline, length of follow-up, socio-demographic variables (age, gender, socio-economic status, ethnicity and 
marital status), medications, comorbid mental disorders (anxiety and substance use disorders), behavioral cardiovascular risk factors (physical activity and smoking status) and 
physical cardiovascular risk factors (BMI, diabetes, hypertension and dyslipidemia) at baseline. “No mood disorders” considered as the comparison group. 
Associations between inflammatory markers and a current diagnosis of bipolar disorder could not be assessed due to small sample size. 
ᵃ Multiple regression with logarithmically transformed cytokine (n = 2796) or hsCRP concentrations (n = 2896). 
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TABLE 4: Associations between inflammatory markers at baseline and mood disorders at follow-up (n=2580) 
Levels of 
Inflammatory 
marker at 
baseline 
Bipolar disorder   MDD   
MDD Combined 
Subtype 
  MDD Atypical Subtype   
MDD Melancholic 
Subtype 
  
MDD Unspecified 
Subtype 
n = 13  n = 608  n = 67  n = 129  n = 155  n = 257 
OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value 
Model 1                                               
IL-6 [pg/ml] 0.68 (0.37-1.25) 0.215  0.96 (0.88-1.06) 0.436  0.95 (0.74-1.22) 0.703  0.87 (0.73-1.05) 0.153  1.04 (0.88-1.22) 0.674  0.96 (0.84-1.09) 0.497 
TNF-α [pg/ml] 0.75 (0.40-1.41) 0.372  0.86 (0.78-0.95) 0.002  1.02 (0.80-1.30) 0.889  0.83 (0.69-1.00) 0.046  0.90 (0.76-1.06) 0.214  0.86 (0.75-0.98) 0.023 
hsCRP [mg/l] 0.98 (0.56-1.69) 0.929   0.93 (0.85-1.03) 0.148   1.03 (0.81-1.32) 0.786   0.98 (0.82-1.18) 0.849   0.87 (0.74-1.03) 0.101   0.94 (0.82-1.07) 0.312 
Model 2                                               
IL-6 [pg/ml] 0.74 (0.35-1.56) 0.431  1.01 (0.91-1.12) 0.857  0.94 (0.72-1.23) 0.642  0.88 (0.72-1.08) 0.221  1.08 (0.91-1.28) 0.386  1.02 (0.88-1.17) 0.826 
TNF-α [pg/ml] 0.75 (0.34-1.63) 0.467  0.85 (0.77-0.95) 0.003  1.05 (0.81-1.36) 0.713  0.85 (0.69-1.04) 0.117  0.88 (0.74-1.05) 0.162  0.86 (0.74-0.99) 0.034 
hsCRP [mg/l] 1.10 (0.57-2.12) 0.772   0.90 (0.81-1.00) 0.054   1.05 (0.80-1.38) 0.704   0.88 (0.72-1.08) 0.219   0.94 (0.79-1.14) 0.544   0.90 (0.78-1.04) 0.143 
Abbreviations: IL-6 = Interleukin-6; TNF-α = Tumor Necrosis Factor-α; hsCRP = high sensitivity C-Reactive Protein; OR = odds ratio; CI = confidence interval; MDD = major depressive 
disorder. 
Model 1: adjusted for the corresponding mental disorder at baseline. 
Model 2: adjusted for the corresponding mental disorder at baseline, length of follow-up, socio-demographic variables (gender, age, socio-economic status, ethnicity and marital 
status), medications, health-related behaviors (former smoker, current smoker and physical inactivity), and physical cardiovascular risk factors (body mass index, diabetes, 
dyslipidemia and hypertension) at baseline. 
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Mood disorders  Inflammation InflammationMood disorders 
BASELINE 
CoLaus (physical exam) baseline 
Age 35-66 years old 
n = 5 535 
PsyCoLaus (psychiatric exam) baseline 
n = 3 719 
Missing mental disorders diagnostic 
n = 9 
Missing inflammatory markers 
n = 61 
CoLaus follow-up 
n = 3 191 
Final sample 
Mood disorders  Inflammation 
n = 3 118 
Cytokines 
n = 2 796 
hsCRP 
n = 2 896 
PsyCoLaus follow-up 
n = 2 848 
Missing inflammatory markers 
n = 258 
Missing mental disorders 
diagnostic 
Final sample 
Inflammation  Mood disorders 
n = 2 580 
Missing cardiovascular risk factors 
n = 3 
Missing cardiovascular risk factors 
n = 2 
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Figure 1. Flow chart of the study for the association between mood disorders at baseline and inflammatory markers at follow-up and for the 
association between inflammatory markers at baseline and mood disorders at follow-up. Abbreviation: hsCRP, high-sensitivity C-Reactive 
Protein.      Baseline assessment;       Follow-up assessment for the association between mood disorders at baseline and inflammatory markers at 
follow-up;      Follow-up sample for the association between inflammatory markers at baseline and mood disorders at follow-up. 
 
